05.2021

APIM Therapeutics announced today completion of a private placement round by existing and new investors. With the proceeds from the private placement, the company will initiate a proof-of-concept combination study in recurrent ovarian cancer and support a Phase-2 investigator-initiated study in sarcoma. For a copy of the corresponding press release, please follow this link.